Skip to main content
  • AETC National Coordinating Resource Center
  • Resources for Clinicians
  • AETC Directory
  • Download App
Home

Breadcrumb

  1. Home
  2. Antiretrovirals

Nucleoside reverse transcriptase inhibitors

U.S. Guidelines Links
Characteristics of Nucleoside Reverse Transcriptase Inhibitors
NRTI, Fixed-Dose Combination Tablets
Other Reference Links
National HIV Curriculum
Abbreviation(s)
NRTI
ARVs
Abacavir
Emtricitabine
Lamivudine
Tenofovir Disoproxil Fumarate
Tenofovir Alafenamide
Zidovudine
Displaying 1 - 4 of 4
Interaction Color Code Clinical Bottom Line Clinical Effects Drug 1 effect Drug 2 dose Drug 2 effect Management
Tenofovir Disoproxil Fumarate
Lamivudine
Emtricitabine
Abacavir
Subscribe to Nucleoside reverse transcriptase inhibitors
Related Co-medications
Abacavir
Emtricitabine
Lamivudine
Tenofovir Alafenamide
Tenofovir Disoproxil Fumarate
Zidovudine
Abacavir / Lamivudine / Zidovudine
  • About
  • Contact Us
  • Log in

Apple Store

   Google Play

This project is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award (grant number U1OHA28686) totaling $1,700,000 with 0% financed with non-governmental sources. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by HRSA, HHS, or the U.S. Government.